Short Interest in Moleculin Biotech, Inc. (NASDAQ:MBRX) Grows By 1,169.5%

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the recipient of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 2,200,000 shares, an increase of 1,169.5% from the January 31st total of 173,300 shares. Approximately 54.6% of the shares of the company are sold short. Based on an average trading volume of 5,000,000 shares, the days-to-cover ratio is currently 0.4 days.

Analyst Ratings Changes

Several equities research analysts have issued reports on MBRX shares. Maxim Group downgraded shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. StockNews.com assumed coverage on shares of Moleculin Biotech in a report on Tuesday. They set a “sell” rating on the stock.

Moleculin Biotech Trading Up 2.0 %

NASDAQ:MBRX opened at $1.29 on Friday. Moleculin Biotech has a fifty-two week low of $0.40 and a fifty-two week high of $10.35. The stock has a fifty day moving average price of $1.55 and a 200-day moving average price of $2.17.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.